Resperidone is an atypical antipsychotic developed by janssen-cilag and was approved by the united states food and drug administration (fda) in 1993 for the treatment of schizophrenia. On august 22, 2007, risperdal was approved as the only drug agent available for treatment of schizophrenia in youth ages 1318; it was also approved that same day for treatment of bipolar disorder in youth and children ages 1018, joining lithium.